- Home
- CMA vs CORT Comparison
CMA vs CORT Comparison
Compare CMA & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMA
- CORT
- Stock Information
- Founded
- CMA 1849
- CORT 1998
- Country
- CMA United States
- CORT United States
- Employees
- CMA N/A
- CORT N/A
- Industry
- CMA Major Banks
- CORT Biotechnology: Pharmaceutical Preparations
- Sector
- CMA Finance
- CORT Health Care
- Exchange
- CMA Nasdaq
- CORT Nasdaq
- Market Cap
- CMA 10.0B
- CORT 7.6B
- IPO Year
- CMA N/A
- CORT N/A
- Fundamental
- Price
- CMA $77.18
- CORT $71.99
- Analyst Decision
- CMA Hold
- CORT Strong Buy
- Analyst Count
- CMA 22
- CORT 4
- Target Price
- CMA $71.86
- CORT $139.00
- AVG Volume (30 Days)
- CMA 4.1M
- CORT 962.0K
- Earning Date
- CMA 10-17-2025
- CORT 11-04-2025
- Dividend Yield
- CMA 3.66%
- CORT N/A
- EPS Growth
- CMA 30.51
- CORT N/A
- EPS
- CMA 5.23
- CORT 1.11
- Revenue
- CMA $3,234,000,000.00
- CORT $716,080,000.00
- Revenue This Year
- CMA $6.48
- CORT $28.85
- Revenue Next Year
- CMA $3.12
- CORT $34.98
- P/E Ratio
- CMA $14.85
- CORT $64.21
- Revenue Growth
- CMA 2.31
- CORT 25.71
- 52 Week Low
- CMA $48.12
- CORT $42.01
- 52 Week High
- CMA $83.22
- CORT $117.33
- Technical
- Relative Strength Index (RSI)
- CMA 56.22
- CORT 38.48
- Support Level
- CMA $76.46
- CORT $70.89
- Resistance Level
- CMA $79.00
- CORT $74.77
- Average True Range (ATR)
- CMA 2.09
- CORT 4.05
- MACD
- CMA -0.23
- CORT -1.07
- Stochastic Oscillator
- CMA 53.26
- CORT 14.14
About CMA Comerica Incorporated
With assets of around $80 billion, Comerica is primarily a relationship-based commercial bank headquartered in Dallas. In addition to Texas, Comerica's other primary geographies are California and Michigan, with locations also in Arizona and Florida and select businesses operating in several other states as well as Canada and Mexico.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.